共 50 条
Prevention of stroke for clinical purposes
被引:0
作者:
Grotemeyer, K-H.
[1
]
Grotemeyer, K. C.
[1
]
机构:
[1] Klinikum Saarbrucken, Neurol Klin, D-66119 Saarbrucken, Germany
关键词:
Stroke;
secondary prevention;
aggregation inhibitors;
anti-coagulation;
costs;
ACETYLSALICYLIC-ACID;
SECONDARY PREVENTION;
ATRIAL-FIBRILLATION;
DOUBLE-BLIND;
ASPIRIN;
CLOPIDOGREL;
TRIAL;
RISK;
DIPYRIDAMOLE;
ATORVASTATIN;
D O I:
10.1055/s-0038-1627161
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
The physician knows the guidelines from the German Neurology Society (DGN) for the prevention of a second stroke. However, for the treatment of a patient pragmatism is necessary and the costs for the system have to be regarded. Furthermore, clinical studies can leave unanswered questions. For the choice of the aggregation inhibitor the individual situation of the patient should be regarded. Blood pressure has to be observed and regulated. Lipid-lowering agents are effective for elderly patients as prevention, but not as first choice treatment. For every medical treatment, practical and clinical usefulness should be regarded.
引用
收藏
页码:789 / +
页数:6
相关论文
共 50 条